Giulio Marchesini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8333779/publications.pdf

Version: 2024-02-01

417 papers	56,626 citations	3930 88 h-index	1187 228 g-index
427 all docs	427 docs citations	427 times ranked	41976 citing authors

#	Article	IF	Citations
1	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	13.9	8,841
2	EASLâ€“EASDâ€“EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 1388-1402.	1.8	3,403
3	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334.	13.9	2,809
4	The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45, 846-854.	3.6	2,448
5	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003, 37, 917-923.	3.6	2,276
6	Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome. Diabetes, 2001, 50, 1844-1850.	0.3	2,100
7	Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine, 1999, 107, 450-455.	0.6	1,412
8	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 2002, 123, 134-140.	0.6	1,332
9	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	1.8	1,157
10	Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.	3.6	1,118
11	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
12	Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology, 2005, 42, 987-1000.	3.6	730
13	Metformin in non-alcoholic steatohepatitis. Lancet, The, 2001, 358, 893-894.	6.3	647
14	A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2005, 100, 1082-1090.	0.2	631
15	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 2008, 48, 792-798.	3.6	600
16	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology, 2003, 124, 1792-1801.	0.6	554
17	Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology, 2005, 42, 473-480.	3.6	554
18	Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease, 2015, 47, 181-190.	0.4	551

#	Article	IF	Citations
19	Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. Seminars in Liver Disease, 2001, 21, 017-026.	1.8	526
20	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, The, 2017, 389, 1399-1409.	6.3	502
21	Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology, 2001, 120, 170-178.	0.6	431
22	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology, 2004, 39, 179-187.	3.6	394
23	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia, 2008, 51, 1947-1953.	2.9	374
24	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51, 1158-1167.	3.6	371
25	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts, 2016, 9, 65-90.	1.6	371
26	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3498-3504.	1.8	370
27	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
28	Insulin Resistance in Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2010, 16, 1941-1951.	0.9	321
29	Nonalcoholic fatty liver disease and the metabolic syndrome. Current Opinion in Lipidology, 2005, 16, 421-427.	1.2	309
30	Compulsive exercise to control shape or weight in eating disorders: prevalence, associated features, and treatment outcome. Comprehensive Psychiatry, 2008, 49, 346-352.	1.5	300
31	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation, 2019, 103, 22-27.	0.5	296
32	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. American Journal of Gastroenterology, 2007, 102, 1251-1258.	0.2	274
33	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Reviews, 2004, 5, 27-42.	3.1	263
34	Obesity-Associated Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, s74-s80.	1.8	260
35	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
36	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.4	254

#	Article	IF	Citations
37	Weight Loss Expectations in Obese Patients and Treatment Attrition: An Observational Multicenter Study. Obesity, 2005, 13, 1961-1969.	4.0	246
38	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 138, 905-912.	0.6	246
39	Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. Liver Transplantation, 2008, 14, 1648-1654.	1.3	242
40	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology, 2016, 63, 2032-2043.	3.6	239
41	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
42	ESPEN Guidelines on Parenteral Nutrition: Hepatology. Clinical Nutrition, 2009, 28, 436-444.	2.3	222
43	Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care, 2011, 34, 1369-1371.	4.3	215
44	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 2020, 71, 1213-1227.	3.6	209
45	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology, 2008, 47, 746-754.	3.6	204
46	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 272-282.	0.4	202
47	Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. Journal of Hepatology, 1990, 11, 92-101.	1.8	201
48	Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 37.	1.1	177
49	Prognostic significance of diabetes in patients with cirrhosis*1. Hepatology, 1994, 20, 119-125.	3.6	175
50	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. American Journal of Gastroenterology, 2008, 103, 1136-1144.	0.2	170
51	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 510-518.	1.9	169
52	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. Journal of Hepatology, 2015, 62, 928-933.	1.8	162
53	Prognostic significance of diabetes in patients with cirrhosis. Hepatology, 1994, 20, 119-125.	3.6	161
54	Cognitive-Behavioral Strategies to Increase the Adherence to Exercise in the Management of Obesity. Journal of Obesity, 2011, 2011, 1-11.	1.1	156

#	Article	IF	Citations
55	Review article: the diagnosis of nonâ€alcoholic fatty liver disease â€“ availability and accuracy of nonâ€invasive methods. Alimentary Pharmacology and Therapeutics, 2013, 37, 392-400.	1.9	156
56	Psychological status and depression in patients with liver cirrhosis. Digestive and Liver Disease, 2005, 37, 593-600.	0.4	154
57	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
58	Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology, 1998, 115, 947-953.	0.6	144
59	The Effect of Lutein on Eye and Extra-Eye Health. Nutrients, 2018, 10, 1321.	1.7	142
60	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology, 2009, 50, 697-706.	3.6	140
61	Predictors of healthâ€related quality of life in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics, 2009, 30, 469-476.	1.9	140
62	Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized crossâ€over comparison. Journal of Internal Medicine, 1993, 233, 385-392.	2.7	137
63	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 2006, 44, 1648-1655.	3.6	137
64	Total and functional hepatic blood flow decrease in parallel with ageing. Age and Ageing, 1999, 28, 29-33.	0.7	136
65	Branched-chain amino acids for people with hepatic encephalopathy. The Cochrane Library, 2017, 5, CD001939.	1.5	136
66	Galactose elimination capacity and liver volume in aging man. Hepatology, 1988, 8, 1079-1083.	3.6	135
67	NASH: From liver diseases to metabolic disorders and back to clinical hepatology. Hepatology, 2002, 35, 497-499.	3.6	130
68	Aminotransferase and gamma-glutamyl transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. Journal of Endocrinological Investigation, 2005, 28, 333-339.	1.8	130
69	WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabetic Medicine, 2004, 21, 383-387.	1.2	129
70	Health-related quality of life in patients with thyroid disorders. Quality of Life Research, 2004, 13, 45-54.	1.5	126
71	Intrauterine Growth Retardation, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in Children. Diabetes Care, 2007, 30, 2638-2640.	4.3	123
72	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020, 72, 14-24.	1.8	123

#	Article	IF	Citations
73	Metabolic Syndrome and NASH. Clinics in Liver Disease, 2007, 11, 105-117.	1.0	119
74	Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study. Clinical Therapeutics, 2008, 30, 1168-1176.	1.1	119
75	Echo-doppler measurement of splanchnic blood flow in control and cirrhotic subjects. Journal of Clinical Ultrasound, 1986, 14, 429-435.	0.4	115
76	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	1.8	114
77	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. Hepatology, 2012, 55, 1317-1323.	3.6	113
78	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis, 2014, 232, 99-109.	0.4	113
79	Diabetes and liver disease: An ominous association. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 63-70.	1.1	112
80	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e87523.	1.1	112
81	Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports, 2021, 3, 100322.	2.6	109
82	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	1.8	107
83	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 935-944.e3.	2.4	102
84	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica, 2013, 50, 569-577.	1.2	101
85	Management of non-alcoholic fatty liver disease. BMJ, The, 2021, 372, m4747.	3.0	99
86	Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. International Journal of Obesity, 2006, 30, 1132-1137.	1.6	93
87	Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials. Journal of Nutrition, 2013, 143, 1263-1268.	1.3	92
88	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired Î²-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2100-2105.	1.8	92
89	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. Journal of Hepatology, 1993, 17, 56-61.	1.8	90
90	Muscle protein breakdown in liver cirrhosis and the role of altered carbohydrate metabolism. Hepatology, 1981, 1, 294-299.	3.6	89

#	Article	IF	Citations
91	Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology, 1996, 23, 1084-1092.	3.6	89
92	Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. Metabolic Brain Disease, 2013, 28, 221-225.	1.4	88
93	Anticatabolic Effect of Branched-Chain Amino Acid-Enriched Solutions in Patients with Liver Cirrhosis. Hepatology, 1982, 2, 420S-425S.	3.6	87
94	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Digestive Diseases and Sciences, 1991, 36, 1197-1203.	1.1	86
95	NAFLD incidence and remission: Only a matter of weight gain and weight loss?. Journal of Hepatology, 2015, 62, 15-17.	1.8	84
96	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 533-542.	1.1	83
97	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. Journal of Hepatology, 2018, 69, 1155-1163.	1.8	80
98	Insulin and glucagon levels in liver cirrhosis. Digestive Diseases and Sciences, 1979, 24, 594-601.	1.1	78
99	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. Diabetes and Metabolism, 2016, 42, 142-156.	1.4	78
100	Portal venous flow in response to acute Î²-blocker and vasodilatatory treatment in patients with liver cirrhosis. Hepatology, 1986, 6, 1248-1251.	3.6	77
101	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2019, 51, 190-205.	0.4	77
102	Non-alcoholic fatty liver and insulin resistance: a causeâ€“effect relationship?. Digestive and Liver Disease, 2004, 36, 165-173.	0.4	76
103	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012, 5, 213.	1.1	74
104	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. Journal of Hepatology, 2013, 58, 771-777.	1.8	74
105	Clinical and psychological correlates of health-related quality of life in obese patients. Health and Quality of Life Outcomes, 2010, 8, 90.	1.0	72
106	Glucose disposal, Î²-cell secretion, and hepatic insulin extraction in cirrhosis: A minimal model assessment. Gastroenterology, 1990, 99, 1715-1722.	0.6	71
107	Lactitol in treatment of chronic hepatic encephalopathy. Digestive Diseases and Sciences, 1993, 38, 916-922.	1.1	71
108	Continuous care in the treatment of obesity: an observational multicentre study. Journal of Internal Medicine, 2005, 258, 265-273.	2.7	71

#	Article	IF	Citations
109	Overview of Randomized Clinical Trials of Oral Branchedâ€Chain Amino Acid Treatment in Chronic Hepatic Encephalopathy. Journal of Parenteral and Enteral Nutrition, 1996, 20, 159-164.	1.3	70
110	Psychological Variables Associated with Weight Loss in Obese Patients Seeking Treatment at Medical Centers. Journal of the American Dietetic Association, 2009, 109, 2010-2016.	1.3	70
111	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with <scp>NAFLD</scp> using the <scp>SAF</scp> score as histological reference. Alimentary Pharmacology and Therapeutics, 2016, 44, 877-889.	1.9	70
112	Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. International Journal of Obesity, 2008, 32, 185-191.	1.6	69
113	Branched-Chain Amino Acid Supplementation in Patients with Liver Diseases. Journal of Nutrition, 2005, 135, 1596S-1601S.	1.3	68
114	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 624-631.	1.1	67
115	Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut, 2007, 56, 1296-1301.	6.1	66
116	Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2136-2141.	1.8	65
117	The treatment of hepatic encephalopathy. Metabolic Brain Disease, 2007, 22, 389-405.	1.4	65
118	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology, 2009, 49, 195-203.	3.6	65
119	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 141-149.	0.2	64
120	Health and ageing: A cross-sectional study of body composition. Clinical Nutrition, 2013, 32, 569-578.	2.3	64
121	Weight Loss Expectations in Obese Patients Seeking Treatment at Medical Centers. Obesity, 2004, 12, 2005-2012.	4.0	63
122	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 684-698.	1.1	63
123	Zinc supplementation improves glucose disposal in patients with cirrhosis. Metabolism: Clinical and Experimental, 1998, 47, 792-798.	1.5	62
124	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. Critical Care, 2013, 17, R53.	2.5	62
125	Major factors for facilitating change in behavioral strategies to reduce obesity. Psychology Research and Behavior Management, 2013, 6, 101.	1.3	62
126	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 373.	1.1	62

#	Article	IF	Citations
127	Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance. Digestive Diseases and Sciences, 1980, 25, 763-768.	1.1	61
128	Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. Journal of Hepatology, 1995, 23, 129-134.	1.8	60
129	Defective methionine metabolism in cirrhosis: Relation to severity of liver disease. Hepatology, 1992, 16, 149-155.	3.6	59
130	Prevalence of Sexual Dysfunction Among Postmenopausal Women with and Without Metabolic Syndrome. Journal of Sexual Medicine, 2012, 9, 434-441.	0.3	59
131	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	1.1	59
132	Cardiovascular disease in cirrhosis A point-prevalence study in relation to glucose tolerance. American Journal of Gastroenterology, 1999, 94, 655-662.	0.2	58
133	Psychological Distress in Morbid Obesity in Relation to Weight History. Obesity Surgery, 2007, 17, 391-399.	1.1	57
134	Prevention and Treatment of Sarcopenic Obesity in Women. Nutrients, 2019, 11, 1302.	1.7	57
135	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	6.1	57
136	Low Ghrelin Concentrations in Nonalcoholic Fatty Liver Disease Are Related to Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5674-5679.	1.8	56
137	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Current Diabetes Reports, 2007, 7, 175-180.	1.7	56
138	Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis. Journal of Hepatology, 1987, 4, 108-117.	1.8	55
139	Quantification of gluconeogenesis in cirrhosis: Response to glucagon. Gastroenterology, 1998, 115, 1530-1540.	0.6	55
140	Retinolâ€binding protein 4: A new marker of virusâ€induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology, 2008, 48, 28-37.	3.6	55
141	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. Journal of Endocrinological Investigation, 2008, 31, 146-152.	1.8	55
142	The Effect of Lifestyle Changes in Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2010, 28, 267-273.	0.8	55
143	Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. International Journal of Obesity, 2004, 28, 1456-1462.	1.6	54
144	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 3, 373-385.	1.1	54

#	Article	IF	Citations
145	A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. Nutrition, 2014, 30, 696-701.	1.1	51
146	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e41183.	1.1	51
147	Blood Alcohol Concentration and Management of Road Trauma Patients in the Emergency Department. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 50, 521-528.	1.1	50
148	Insulin-dependent metabolism of branched-chain amino acids in obesity. Metabolism: Clinical and Experimental, 1984, 33, 147-150.	1.5	49
149	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. Journal of Hepatology, 1996, 25, 474-480.	1.8	49
150	The metabolic syndrome in treatment-seeking obese persons. Metabolism: Clinical and Experimental, 2004, 53, 435-440.	1.5	49
151	Gender, fatty liver and GGT. Hepatology, 2006, 44, 278-279.	3.6	49
152	Visceral Fat and Body Composition Changes in a Female Population After RYGBP: a Two-Year Follow-Up by DXA. Obesity Surgery, 2015, 25, 443-451.	1.1	49
153	Costs associated with emergency care and hospitalization for severe hypoglycemia. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 345-351.	1.1	49
154	Glutathione kinetics in normal man and in patients with liver cirrhosis. Journal of Hepatology, 1997, 26, 606-613.	1.8	48
155	Reduced quality of life of patients with hepatocellular carcinoma. Digestive and Liver Disease, 2003, 35, 46-54.	0.4	48
156	Night eating syndrome in class IIâ€“III obesity: metabolic and psychopathological features. International Journal of Obesity, 2009, 33, 899-904.	1.6	48
157	Clinical Performance of NICE Recommendations versus NCWFNS Proposal in Patients with Mild Head Injury. Journal of Neurotrauma, 2005, 22, 1419-1427.	1.7	47
158	Vascular Risk in Young Women With Polycystic Ovary and Polycystic Ovary Syndrome. Obstetrics and Gynecology, 2008, 111, 385-395.	1.2	46
159	Acquired hepatocerebral degeneration: full recovery after liver transplantation. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 136-137.	0.9	45
160	Underweight eating disorder without overâ€evaluation of shape and weight: Atypical anorexia nervosa?. International Journal of Eating Disorders, 2008, 41, 705-712.	2.1	45
161	Construct Validity of the Short Formâ€36 Health Survey and Its Relationship with BMI in Obese Outpatients. Obesity, 2006, 14, 1429-1437.	1.5	44
162	Cognitiveâ€Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Scoreâ€Adjusted Observational Study. Obesity, 2011, 19, 763-770.	1.5	44

#	Article	IF	Citations
163	Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clinical Pharmacology: Advances and Applications, 2013, 5, 167.	0.8	44
164	Branched-chain amino acids for people with hepatic encephalopathy. , 2015, , CD001939.		44
165	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. Medicine (United States), 2016, 95, e3446.	0.4	44
166	The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 944-950.	1.1	44
167	Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Digestive and Liver Disease, 2000, 32, 398-405.	0.4	43
168	Effects of cognitiveâ€“behavioural therapy on health-related quality of life in obese subjects with and without binge eating disorder. International Journal of Obesity, 2002, 26, 1261-1267.	1.6	43
169	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovascular Diabetology, 2018, 17, 28.	2.7	43
170	Physical activity for the prevention and treatment of metabolic disorders. Internal and Emergency Medicine, 2013, 8, 655-666.	1.0	41
171	Branched-chain amino acids and alanine as indices of the metabolic control in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1982, 22, 217-9.	2.9	40
172	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. Digestive and Liver Disease, 2004, 36, 406-411.	0.4	40
173	Response to: Comment to â€œEASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver diseaseâ€. Journal of Hepatology, 2017, 66, 466-467.	1.8	40
174	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1346-1353.	1.1	39
175	Thyroid involvement in chronic inflammatory rheumatological disorders. Clinical Rheumatology, 1993, 12, 479-484.	1.0	38
176	Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology, 1996, 24, 1047-1052.	3.6	38
177	Update on nutritional supplementation with branched-chain amino acids. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 83-87.	1.3	37
178	Evaluation of liver volume and liver function following hepatic resection in man. Liver, 1986, 6, 286-291.	0.1	37
179	Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertility and Sterility, 2009, 91, 2537-2544.	0.5	37
180	The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study. Behaviour Research and Therapy, 2014, 63, 157-161.	1.6	37

#	Article	IF	Citations
181	Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa?. Behaviour Research and Therapy, 2008, 46, 1290-1294.	1.6	36
182	Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1275-1279.	0.9	36
183	The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 339-346.	1.1	36
184	Pathogenetic Mechanisms and Cardiovascular Risk. Diabetes Care, 2012, 35, 2607-2612.	4.3	36
185	Snoring, hypertension and Type 2 diabetes in obesity. Protection by physical activity. Journal of Endocrinological Investigation, 2004, 27, 150-157.	1.8	35
186	The Effect of Obesity Management on Body Image in Patients Seeking Treatment at Medical Centers. Obesity, 2007, 15, 2320-2327.	1.5	35
187	A randomized trial of energyâ€restricted highâ€protein versus highâ€carbohydrate, lowâ€fat diet in morbid obesity. Obesity, 2013, 21, 1774-1781.	1.5	35
188	Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. Acta Diabetologica, 2014, 51, 559-566.	1.2	35
189	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. Digestive and Liver Disease, 2017, 49, 235-240.	0.4	35
190	Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. World Journal of Gastroenterology, 2010, 16, 348.	1.4	35
191	Plasma amino acid response to protein ingestion in patients with liver cirrhosis. Gastroenterology, 1983, 85, 283-290.	0.6	34
192	Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. Hepatology, 1991, 13, 460-466.	3.6	34
193	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 1105-1116.	1.0	34
194	The effect of inpatient cognitive-behavioral therapy for eating disorders on temperament and character. Behaviour Research and Therapy, 2007, 45, 1335-1344.	1.6	34
195	Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones. Drug Safety, 2012, 35, 315-323.	1.4	34
196	Weight Loss Expectations and Attrition in Treatment-Seeking Obese Women. Obesity Facts, 2015, 8, 311-318.	1.6	34
197	Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases. Proceedings of the IEEE, 2018, 106, 723-737.	16.4	34
198	Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis. , 2020, 2, e0152.		34

#	Article	IF	Citations
199	Nutritional effects of oral zinc supplementation in cirrhosis. Nutrition Research, 2000, 20, 1079-1089.	1.3	33
200	A physical activity program to reinforce weight maintenance following a behavior program in overweight/obese subjects. International Journal of Obesity, 2006, 30, 697-703.	1.6	33
201	Effect of Euglycemic Insulin Infusion on Plasma Levels of Branched-Chain Amino Acids in Cirrhosis. Hepatology, 2007, 3, 184-187.	3.6	33
202	Weight management, psychological distress and binge eating in obesity. A reappraisal of the problem. Appetite, 2010, 54, 269-273.	1.8	33
203	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Hepatology, 2013, 59, 1169-1176.	1.8	33
204	The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1181-1188.	1.1	33
205	Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting. Resuscitation, 2006, 71, 180-187.	1.3	32
206	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 1105-1116.	1.0	32
207	Update on branched-chain amino acid supplementation in liver diseases. Current Opinion in Gastroenterology, 2005, 21, 197-200.	1.0	31
208	Metabolic Syndrome and Insulin Resistance in Subjects with Morbid Obesity. Obesity Surgery, 2010, 20, 295-301.	1.1	31
209	Obesity in the Context of Aging: Quality of Life Considerations. Pharmacoeconomics, 2015, 33, 655-672.	1.7	31
210	Adverse events with sodium-glucose co-transporter-2 inhibitors: AÂglobal analysis of international spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1098-1107.	1.1	31
211	Splanchnic vein measurements in patients with liver cirrhosis: a case-control study.. Journal of Ultrasound in Medicine, 1985, 4, 641-646.	0.8	30
212	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. British Journal of Clinical Pharmacology, 2007, 63, 346-355.	1.1	30
213	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut, 2011, 60, 108-115.	6.1	30
214	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 380-386.	1.1	30
215	Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. Journal of Hepatology, 2016, 64, 262-264.	1.8	30
216	Hepatic Encephalopathy and Health-Related Quality of Life. Clinics in Liver Disease, 2012, 16, 159-170.	1.0	29

#	Article	IF	Citations
217	Branched-chain amino acids for people with hepatic encephalopathy. , 2015, , CD001939.		29
218	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. Digestive Diseases, 2016, 34, 3-10.	0.8	29
219	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. Nutrients, 2019, 11, 3048.	1.7	29
220	Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis. Metabolism: Clinical and Experimental, 2000, 49, 1434-1439.	1.5	28
221	A rapid method for the in vivo measurement of liver volume. Liver, 1989, 9, 159-163.	0.1	28
222	A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity. Diabetology and Metabolic Syndrome, 2014, 6, 74.	1.2	28
223	Under-treatment of migrants with diabetes in a universalistic health care system: The ARNO Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 393-399.	1.1	28
224	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 193-200.	1.8	28
225	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. Nutrients, 2021, 13, 2748.	1.7	28
226	An empowerment-based educational program improves psychological well-being and health-related quality of life in Type 1 diabetes. Journal of Endocrinological Investigation, 2006, 29, 405-412.	1.8	27
227	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Digestive and Liver Disease, 2011, 43, 404-410.	0.4	27
228	Personality features of obese women in relation to binge eating and night eating. Psychiatry Research, 2013, 207, 86-91.	1.7	27
229	Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?. World Journal of Gastroenterology, 2014, 20, 10128.	1.4	27
230	The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease, 2014, 18, 73-89.	1.0	27
231	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A realâ€world data analysis. Liver International, 2021, 41, 731-742.	1.9	27
232	European â€˜NAFLD Preparedness Indexâ€™ â€” Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	2.6	27
233	Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion. Diabetologia, 1982, 23, 456-8.	2.9	26
234	Is liver disease a threat to patients with metabolic disorders?. Annals of Medicine, 2005, 37, 333-346.	1.5	26

#	Article	IF	Citations
235	The Influence of Weight-Loss Expectations on Weight Loss and of Weight-Loss Satisfaction on Weight Maintenance in Severe Obesity. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 32-38.	0.4	26
236	Ultrasonographic follow-up of liver cirrhosis. Journal of Clinical Ultrasound, 1990, 18, 91-96.	0.4	25
237	A Positive Blood Alcohol Concentration Is the Main Predictor of Recurrent Motor Vehicle Crash. Annals of Emergency Medicine, 2005, 46, 161-167.	0.3	25
238	Self-induced vomiting in eating disorders: Associated features and treatment outcome. Behaviour Research and Therapy, 2009, 47, 680-684.	1.6	25
239	Night eating syndrome and weight loss outcome in obese patients. International Journal of Eating Disorders, 2011, 44, 150-156.	2.1	25
240	A controlled, classâ€based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity. Pediatric Obesity, 2012, 7, 436-445.	1.4	25
241	Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study. Metabolic Syndrome and Related Disorders, 2013, 11, 412-416.	0.5	25
242	Pancreatic Î²-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal. Metabolism: Clinical and Experimental, 1985, 34, 695-701.	1.5	24
243	NAFLD treatment: Cognitive-behavioral therapy has entered the arena. Journal of Hepatology, 2005, 43, 926-928.	1.8	24
244	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1014-1022.	1.1	24
245	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. Journal of Hepatology, 2021, 74, 972-974.	1.8	24
246	Thyroid gland size and function in patients with cirrhosis of the liver. Liver, 1991, 11, 71-77.	0.1	23
247	Kinetics of hepatic aminoâ€nitrogen conversion in ageing man. Liver, 1994, 14, 288-294.	0.1	23
248	Hepatotoxicity of fast food?. Gut, 2008, 57, 568-570.	6.1	23
249	Effects of Cognitive-Behavioral Treatment for Weight Loss in Family Members. Journal of the American Dietetic Association, 2011, 111, 1712-1719.	1.3	23
250	ÂNASH: A glance at the landscape of pharmacological treatment. Annals of Hepatology, 2016, 15, 673-81.	0.6	23
251	The Euglycemic Clamp Technique in Patients with Liver Cirrhosis. Hormone and Metabolic Research, 1984, 16, 341-343.	0.7	22
252	Personality dimensions and treatment drop-outs among eating disorder patients treated with cognitive behavior therapy. Psychiatry Research, 2008, 158, 381-388.	1.7	22

#	Article	IF	Citations
253	Nutritional treatment of chronic liver failure. Hepatology Research, 2008, 38, S93-S101.	1.8	22
254	Double Heterozygous Mutations Involving Both HNF1A/MODY3 and HNF4A/MODY1 Genes. Diabetes Care, 2010, 33, 2336-2338.	4.3	22
255	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. Acta Diabetologica, 2011, 48, 337-343.	1.2	22
256	Non-alcoholic fatty liver disease (NAFLD) - A novel common aspect of the metabolic syndrome. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2006, 150, 101-104.	0.2	22
257	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antiviral Therapy, 2009, 14, 631-639.	0.6	22
258	Emotionally focused group therapy and dietary counseling in binge eating disorder. Effect on eating disorder psychopathology and quality of life. Appetite, 2013, 71, 361-368.	1.8	21
259	Sexuality and Psychopathological Aspects in Premenopausal Women with Metabolic Syndrome. Journal of Sexual Medicine, 2014, 11, 2020-2028.	0.3	21
260	Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 9-17.	1.1	21
261	The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. Hepatology, 1996, 24, 820-823.	3.6	21
262	Synthesis of Urea after a Protein-rich Meal in Normal Man in Relation to Ageing. Age and Ageing, 1990, 19, 4-10.	0.7	20
263	Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon l-thyroxine therapy. Metabolism: Clinical and Experimental, 1993, 42, 1263-1269.	1.5	20
264	Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Research and Clinical Practice, 2004, 63, 143-151.	1.1	20
265	Reduced ubiquinone plasma levels in patients with liver cirrhosis and in chronic alcoholics. Liver, 1994, 14, 138-140.	0.1	20
266	Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 313-320.	1.1	20
267	Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy, 2011, 12, 2657-2672.	0.9	20
268	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. Journal of Viral Hepatitis, 2011, 18, e372-80.	1.0	20
269	Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name..... Journal of Hepatology, 2018, 68, 391-392.	1.8	20
270	Degeneration of the corticospinal tract following portosystelnic shunt associated with spinal cord infarction. Virchows Archiv A, Pathological Anatomy and Histopathology, 1985, 406, 475-481.	1.4	19

#	Article	IF	Citations
271	Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. Digestive Diseases and Sciences, 1987, 32, 1118-1124.	1.1	19
272	Eating behavior affects quality of life in type 2 diabetes mellitus. Eating and Weight Disorders, 2005, 10, 251-257.	1.2	19
273	Analysis of the deterioration rates of liver function in cirrhosis, based on galactose elimination capacity. Liver, 1990, 10, 65-71.	0.1	19
274	Objective and subjective binge eating in underweight eating disorders: Associated features and treatment outcome. International Journal of Eating Disorders, 2012, 45, 370-376.	2.1	19
275	Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure. Hepatology, 1993, 18, 28-35.	3.6	18
276	Reply:. Hepatology, 2006, 43, 1168-1169.	3.6	18
277	Prevention and treatment of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 331-340.	0.4	18
278	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs, 2011, 16, 121-136.	1.0	18
279	Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia. Hepatology, 2012, 55, 1298-1300.	3.6	18
280	A psychological support program for individuals with Type 1 diabetes. Acta Diabetologica, 2013, 50, 209-216.	1.2	18
281	Emotion-Focused Therapy and Dietary Counseling for Obese Patients with Binge Eating Disorder: A Propensity Score-Adjusted Study. Psychotherapy and Psychosomatics, 2013, 82, 193-194.	4.0	18
282	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes, Obesity and Metabolism, 2017, 19, 1594-1601.	2.2	18
283	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1903-1914.	0.9	18
284	Observational research on sodium glucose coâ€transporterâ€2 inhibitors: A real breakthrough?. Diabetes, Obesity and Metabolism, 2018, 20, 2711-2723.	2.2	18
285	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drugâ€“drug interactions through the FDA adverse event reporting system. Acta Diabetologica, 2020, 57, 71-80.	1.2	18
286	Ammonia-induced changes in pancreatic hormones and plasma amino acids in patients with liver cirrhosis. Digestive Diseases and Sciences, 1982, 27, 406-412.	1.1	17
287	Insulin resistance in aged man: Relationship between impaired glucose tolerance and decreased insulin activity on branched-chain amino acids. Metabolism: Clinical and Experimental, 1987, 36, 1096-1100.	1.5	17
288	Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcohol steatohepatitis. Digestive and Liver Disease, 2001, 33, 768-777.	0.4	17

#	Article	IF	Citations
289	Homocysteine and psychological traits: a study in obesity. Nutrition, 2002, 18, 403-407.	1.1	17
290	The changing face of mild head injury: Temporal trends and patterns in adolescents and adults from 1997 to 2008. Injury, 2010, 41, 913-917.	0.7	17
291	Quality of Diabetes Care in Italy: Information From a Large Population-Based Multiregional Observatory (ARNO Diabetes). Diabetes Care, 2012, 35, e64-e64.	4.3	17
292	Evidence of a diurnal thermogenic handicap in obesity. Chronobiology International, 2015, 32, 299-302.	0.9	17
293	Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women. Journal of Sexual Medicine, 2016, 13, 46-54.	0.3	17
294	Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. Journal of Clinical Medicine, 2019, 8, 851.	1.0	17
295	A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1945-1953.	1.1	17
296	Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. BMJ Open Diabetes Research and Care, 2020, 8, e001191.	1.2	17
297	Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Review of Gastroenterology and Hepatology, 2020, 14, 127-135.	1.4	17
298	Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance. Digestive and Liver Disease, 2003, 35, 722-727.	0.4	16
299	Which type of observation for patients with high-risk mild head injury and negative computed tomography?. European Journal of Emergency Medicine, 2004, 11, 65-69.	0.5	16
300	Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 493-498.	1.1	16
301	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 699-705.	1.1	16
302	Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity. Eating and Weight Disorders, 2018, 23, 205-214.	1.2	16
303	Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control. Journal of Endocrinological Investigation, 2018, 41, 307-314.	1.8	16
304	The association between weight maintenance and session-by-session diet adherence, weight loss and weight-loss satisfaction. Eating and Weight Disorders, 2020, 25, 127-133.	1.2	16
305	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis, 2013, 20, 174-182.	1.0	15
306	Longstanding underweight eating disorder: Associated features and treatment outcome. Psychotherapy Research, 2013, 23, 315-323.	1.1	15

#	Article	IF	Citations
307	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1-16.	1.1	15
308	Portal pressure changes induced by medical treatment: US detection.. Radiology, 1985, 155, 763-766.	3.6	14
309	Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition, 1992, 11, 303-308.	2.3	14
310	Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. Digestive and Liver Disease, 2011, 43, 73-77.	0.4	14
311	Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0â€“29 years: The population-based CINECA-SID ARNO Observatory, 2002â€“2012. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1104-1111.	1.1	14
312	Long-term treatment of severe obesity: are lifestyle interventions still an option?. Expert Review of Endocrinology and Metabolism, 2017, 12, 391-400.	1.2	14
313	Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients. Nutrition, 2019, 61, 143-150.	1.1	13
314	Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. Acta Diabetologica, 2019, 56, 289-299.	1.2	13
315	The Effect of Liraglutide on Î²-Blockade for Preventing Variceal Bleeding: A Case Series. Annals of Internal Medicine, 2020, 173, 404-405.	2.0	13
316	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. Transplantation, 2022, 106, 462-478.	0.5	13
317	Thyroid volume in type 1 diabetes patients without overt thyroid disease. Acta Diabetologica, 1995, 32, 49-52.	1.2	12
318	Personality, attrition and weight loss in treatment seeking women with obesity. Clinical Obesity, 2015, 5, 266-272.	1.1	12
319	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 983-990.	1.1	12
320	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive and Liver Disease, 2022, 54, 170-182.	0.4	12
321	Plasma Amino Acids as Markers of Liver Dysfunction in Cirrhotics. Scandinavian Journal of Gastroenterology, 1981, 16, 689-692.	0.6	11
322	Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus. Clinical Nutrition, 1991, 10, 105-113.	2.3	11
323	Weight Loss for a Healthy Liver. Gastroenterology, 2015, 149, 274-278.	0.6	11
324	Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program. Internal and Emergency Medicine, 2017, 12, 45-52.	1.0	11

#	Article	IF	Citations
325	Referral pathways for NAFLD fibrosis in primary care â€“ No longer a â€˜needle in a haystackâ€™. Journal of Hepatology, 2019, 71, 246-248.	1.8	11
326	Nurse-managed basal-bolus versus sliding-scale insulin regimen in subjects with hyperglycemia at admission for orthopedic surgery: a propensity score approach. Acta Diabetologica, 2020, 57, 835-842.	1.2	11
327	Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. Journal of Hepatology, 1996, 25, 498-503.	1.8	10
328	Effects of systemic prostaglandin e on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. Hepatology, 1998, 27, 815-821.	3.6	10
329	A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department. Emergency Medicine Journal, 2004, 21, 317-322.	0.4	10
330	Disease Management of the Metabolic Syndrome in a Community: Study Design and Process Analysis on Baseline Data. Metabolic Syndrome and Related Disorders, 2006, 4, 7-16.	0.5	10
331	Effects of cognitive-behavioral therapy on Eating Disorders: Neurotransmitter secretory response to treatment. Psychoneuroendocrinology, 2010, 35, 729-737.	1.3	10
332	Coffee and tea breaks for liver health. Journal of Hepatology, 2017, 67, 221-223.	1.8	10
333	The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. Diabetes Therapy, 2018, 9, 1037-1047.	1.2	10
334	Polyamine plasma levels and liver regeneration following partial hepatic resection in man. Journal of Hepatology, 1992, 16, 159-164.	1.8	9
335	Transamination of methionine after loading in patients with cirrhosis. Journal of Hepatology, 1996, 24, 95-100.	1.8	9
336	Uncertainty in Liver Function Assessment on the Basis of Single-Point Galactose Concentration. Digestion, 1997, 58, 379-383.	1.2	9
337	Caffeine intake, fasting plasma caffeine and caffeine clearance in patients with liver diseases. Liver, 1988, 8, 241-246.	0.1	9
338	Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes--the lower, the better?. International Journal of Epidemiology, 2011, 40, 1539-1541.	0.9	9
339	Personality Traits in Obesity Associated with Binge Eating and/or Night Eating. Current Obesity Reports, 2014, 3, 120-126.	3.5	9
340	Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool. Clinical Nutrition, 2014, 33, 1087-1094.	2.3	9
341	DXA-assessed changes in body composition in obese women following two different weight loss programs. Nutrition, 2018, 46, 13-19.	1.1	9
342	Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?. Journal of Hepatology, 2019, 71, 1073-1075.	1.8	9

#	Article	IF	Citations
343	Correlations between weightâ€bearing 3D bone architecture and dynamic plantar pressure measurements in the diabetic foot. Journal of Foot and Ankle Research, 2020, 13, 64.	0.7	9
344	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. Acta Diabetologica, 2020, 57, 1117-1119.	1.2	9
345	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. Current Pharmaceutical Design, 2020, 26, 1110-1118.	0.9	9
346	Which Treatment for Nonalcoholic Fatty Liver Disease?. Mini-Reviews in Medicinal Chemistry, 2008, 8, 767-775.	1.1	9
347	Carbohydrate metabolism in hepatocellular carcinoma: Where does the glucose go?. Hepatology, 1989, 10, 253-255.	3.6	8
348	Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. Digestive Diseases and Sciences, 1999, 44, 377-384.	1.1	8
349	Type 2 Diabetes and the Naaman Syndrome. Diabetes Care, 2003, 26, 3195-3195.	4.3	8
350	When the journey from obesity to cirrhosis takes an early start. Journal of Hepatology, 2016, 65, 249-251.	1.8	8
351	Combination of GLPâ€1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. Endocrinology, Diabetes and Metabolism, 2019, 2, e00082.	1.0	8
352	Incidence of diabetes mellitus in Italy in year 2018. A nationwide population-based study of the ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2338-2344.	1.1	8
353	ICD Code Retrieval: Novel Approach for Assisted Disease Classification. Lecture Notes in Computer Science, 2015, , 147-161.	1.0	8
354	Hepatic conversion of amino-nitrogen to urea in thyroid diseases. II. A study in hyperthyroid patients. Metabolism: Clinical and Experimental, 1994, 43, 1023-1029.	1.5	7
355	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. Hepatology, 2004, 39, 1749-1749.	3.6	7
356	Liver in the analysis of body composition by dual-energy X-ray absorptiometry. British Journal of Radiology, 2014, 87, 20140232.	1.0	7
357	Are severe hypoglycemic episodes in diabetes correctly identified by administrative data? Evidence of underreporting from the HYPOTHESIS study. Acta Diabetologica, 2016, 53, 677-680.	1.2	7
358	Symptoms of Starvation in Eating Disorder Patients. , 2011, , 2259-2269.		7
359	Oral BCAA in the treatment of chronic hepatic encephalopathy. Journal of Hepatology, 1991, 12, 267.	1.8	6
360	Disease and comorbidityâ€"effects on quality of life. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 504-506.	8.2	6

#	Article	IF	Citations
361	Analysis of Different Decision Aids for Clinical Use in Pediatric Head Injury in an Emergency Department of a General Hospital. Journal of Trauma, 2011, 70, E79-E83.	2.3	6
362	Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. Hepatology International, 2013, 7, 814-822.	1.9	6
363	Evidence-Based Medicine and the Problem of Healthy Volunteers. Annals of Hepatology, 2017, 16, 832-834.	0.6	6
364	Effects of Systemic Prostaglandin E1 on Splanchnic and Peripheral Haemodynamics in Control Subjects and in Patients with Cirrhosis. Prostaglandins and Other Lipid Mediators, 1998, 55, 209-218.	1.0	5
365	Diabetes prevention strategy in offspring of type 2 diabetic patients with a direct involvement of the diseased parents. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 237-238.	1.1	5
366	Essential hypertension and chronic viral hepatitis. Digestive and Liver Disease, 2007, 39, 466-472.	0.4	5
367	Acute heart failure in the emergency department: a follow-up study. Internal and Emergency Medicine, 2016, 11, 115-122.	1.0	5
368	Statins in liver disease: not only prevention of cardiovascular events. Expert Review of Gastroenterology and Hepatology, 2018, 12, 743-744.	1.4	5
369	Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2661-2668.	1.1	5
370	The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention. International Journal of Clinical and Health Psychology, 2022, 22, 100279.	2.7	5
371	Prognostic Value of Stress Hyperglycemia in Patients Admitted to Medical/Geriatric Departments for Acute Medical Illness. Diabetes Therapy, 2022, 13, 145-159.	1.2	5
372	LONG-TERM MANAGEMENT OF ALCOHOLIC LIVER DISEASE. Clinics in Liver Disease, 1998, 2, 821-838.	1.0	4
373	Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database. Diabetes Care, 2007, 30, e33-e33.	4.3	4
374	Massive Weight Loss Without Surgery in a Super Obese Patient. Obesity Surgery, 2011, 21, 540-545.	1.1	4
375	Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution. BJR|case Reports, 2019, 5, 20170078.	0.1	4
376	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. Expert Opinion on Pharmacotherapy, 2019, 20, 1087-1090.	0.9	4
377	Signal of potentially protective drugâ€“drug interactions from spontaneous reporting systems: proceed with caution. Acta Diabetologica, 2020, 57, 115-116.	1.2	4
378	Sonographic evaluation of liver, spleen, and splanchnic vessels following partial liver resection.. Journal of Ultrasound in Medicine, 1986, 5, 563-567.	0.8	3

#	Article	IF	Citations
379	Nash As Part of the Metabolic (Insulin Resistance) Syndrome. , 0, , 55-65.		3
380	Metabolic Syndrome and Health-Related Quality of Life: Does Psychological Well-Being Matter?. Annals of Epidemiology, 2008, 18, 592-593.	0.9	3
381	Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin. American Journal of Emergency Medicine, 2012, 30, 61-67.	0.7	3
382	NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Current Hepatology Reports, 2016, 15, 103-112.	0.4	3
383	Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 711-720.	0.7	3
384	Motivational Interviewing Adapted to Group Setting for the Treatment of Relapse in the Behavioral Therapy of Obesity. A Clinical Audit. Nutrients, 2020, 12, 3881.	1.7	3
385	Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 977-983.	1.1	3
386	IntÃ©rÃªt de l'administration par voie orale d'acides aminÃ©s Ã chaÃ®ne ramifiÃ©e chez le cirrhotique encÃ©phalopathe chronique. Nutrition Clinique Et Metabolisme, 1991, 5, 207-214.	0.2	2
387	Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis. Metabolism: Clinical and Experimental, 1995, 44, 899-905.	1.5	2
388	Does the liver accelerate ageing: Talking muscles and liver?. Journal of Hepatology, 2017, 66, 8-10.	1.8	2
389	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. Journal of Endocrinological Investigation, 2019, 42, 787-796.	1.8	2
390	The Effect of Neuropathy and Diabetes Type on Multisegment Foot Kinematics: A Cohort Study on 70 Participants with Diabetes. Applied Sciences (Switzerland), 2021, 11, 8848.	1.3	2
391	Mathematical model to analyse urea synthesis following alanine infusion in control subjects and in patients with liver cirrhosis. Medical and Biological Engineering and Computing, 1990, 28, 325-328.	1.6	1
392	Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control. Metabolism: Clinical and Experimental, 2001, 50, 253-258.	1.5	1
393	Effects of long-term oral misoprostol administration on hepatic amino acidâ€“nitrogen metabolism in patients with cirrhosis. Journal of Hepatology, 2002, 37, 15-21.	1.8	1
394	Outcome research in obesity: lessons from the QUOVADIS study. Drug Development Research, 2006, 67, 260-270.	1.4	1
395	Metabolic syndrome: relevant for all types of chronic liver diseases?. Gut, 2010, 59, 1314-1315.	6.1	1
396	Therapeutic hypothermia after cardiac arrest: The Mediterranean-diet Italian style. Resuscitation, 2011, 82, 637-638.	1.3	1

#	Article	IF	Citations
397	Reply to: â€œIndustrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patientsâ€. Journal of Hepatology, 2014, 60, 677-678.	1.8	1
398	How Much Fat Does One Need to Eat to Get a Fatty Liver? A Dietary View of NAFLD. , 2016, , 109-122.		1
399	Switching among Equivalents in Chronic Cardiovascular Therapies: â€˜Real Worldâ€™ Data from Italy. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 63-69.	1.2	1
400	Acute Heart Failure in the Emergency Department: the SAFE-SIMEU Epidemiological Study. Journal of Emergency Medicine, 2017, 53, 178-185.	0.3	1
401	Genes and lifestyle: Which of the two is more relevant in driving NAFLD progression?. Digestive and Liver Disease, 2021, 53, 1433-1434.	0.4	1
402	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
403	Analysis of Clinical Profiles, Deformities, and Plantar Pressure Patterns in Diabetic Foot Syndrome. Applied Sciences (Switzerland), 2021, 11, 11464.	1.3	1
404	A psycho-educational intervention for the prevention of foot lesions in people with diabetes: Report of a clinical audit. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	1
405	Model-derived assessment of urea appearance in response to alanine infusion: A quantitative measure of liver function in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 550-556.	1.4	0
406	Vegetable and animal protein diets. Journal of Internal Medicine, 1994, 236, 102-103.	2.7	0
407	Nutritional therapy in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S401-S405.	1.4	0
408	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. L Endocrinologo, 2007, 8, 136-143.	0.0	0
409	Author's reply: Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy, 2012, 13, 289-290.	0.9	0
410	Impatto delle incretine sulla gestione del paziente diabetico: dati del monitoraggio antidiabetici AIFA. L Endocrinologo, 2012, 13, 210-215.	0.0	0
411	Reply to: â€œIs industrial fructose just a marker of an unhealthy dietary pattern?â€. Journal of Hepatology, 2014, 61, 173-175.	1.8	0
412	Response to letter to the editor: Gallo F etÂal., â€œThe economic burden ofÂsevere hypoglycemia: Two sides of the same coinâ€•Nutr Metab Cardiovasc Dis. 2016;26:850â€“851.. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 851-852.	1.1	0
413	Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opinion on Pharmacotherapy, 2022, 23, 149-153.	0.9	0
414	Effects of Physical Exercise on the Quality of Life of Individuals with Diabetes and Obesity. , 2007, , 191-201.		0

#	Article	IF	Citations
415	Behavioral Aspects of Nonalcoholic Fatty Liver Disease: Diet, Causes, and Treatment. , 2011, , 1833-1844.		0
416	Anthropometry and Nutritional Rehabilitation in Underweight Eating Disorders. , 2012, , 2807-2820.		0
417	Obesity and NAFLD: Same Problem?. , 2020, , 1-14.		0